Medical device and MedTech insights, news, tips and more

New FDA Clearance Makes Eyenuk the First Company with Multiple Cameras for Autonomous AI Detection of Diabetic Retinopathy

June 22, 2023

Eyenuk, a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, has received U.S. Food and Drug Administration (FDA) clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras.

The regulatory clearance of the EyeArt v2.2.0 system makes it the first and only AI system that is FDA-cleared for use with multiple retinal cameras by different manufacturers. This clearance builds upon the EyeArt system’s launch in August 2020 as the first and only AI technology to be cleared by the FDA to detect both more than mild and vision-threatening DR. In the European Union, the EyeArt system is the first and only AI system approved under MDR Class IIb to detect DR, age-related macular degeneration, and glaucomatous optic nerve damage, in a single test.

Since its launch in global markets, the EyeArt system has been used by hundreds of clinics to enable safe and reliable eye screening for over 230,000 patients with diabetes and counting.

“I am particularly thrilled about this clearance as it showcases our extraordinary commitment towards our mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases,” said Kaushal Solanki, PhD, Founder and CEO of Eyenuk. “The EyeArt system can now be used with multiple camera models in the U.S., which significantly expands access for patients who can be screened in their primary care doctor’s office for preventable blindness due to diabetes.”

This latest FDA clearance for the EyeArt v2.2.0 system is based on clinical data from a prospective multi-center clinical trial ( ID NCT04984200) that demonstrated exceptional performance for the Topcon NW400 cameras, as summarized below.

  • 94.4% sensitivity and 91.1% specificity for more than mild DR detection, and
  • 96.8% sensitivity and 91.6% specificity for vision-threatening DR detection

Additionally, with this clearance, the EyeArt system gets an upgraded image quality assessment module and Eyenuk’s proprietary Real-Time Image Quality Feedback solution. These enhancements improve the EyeArt system’s usability, achieving the best-in-class gradability (i.e., percentage of patients with conclusive reports) without the need for dilation.

In the clinical trial, for all camera models (Canon CR-2 AF, Canon CR-2 Plus AF, and Topcon NW400) conclusive EyeArt results were available for 90.4% of cases without needing dilation and for 99% of cases when a small fraction was dilated after the quality feedback solution recommended dilation.

“I am excited that we are bringing several patient- and clinic-friendly product updates to the market through this clearance,” said Malavika Bhaskaranand, Head of Regulatory and Clinical Affairs for Eyenuk. “Real-Time Image Quality Feedback can significantly improve the clinical workflows associated with diabetic eye exams, and achieving best-in-class gradability implies much better patient experience and saving of clinic staff time that otherwise would have been spent on dilation.”

Eyenuk will showcase the newly-cleared EyeArt system at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA 2023) on June 23–26 in San Diego, CA. Demonstrations will be available at booth #527.

About Eyenuk, Inc.

Eyenuk, Inc. is a global artificial intelligence (AI) digital health company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. Find Eyenuk online on its websiteTwitterFacebook, and LinkedIn.

See Full Press Release at the Source: New FDA Clearance Makes Eyenuk the First Company with Multiple Cameras for Autonomous AI Detection of Diabetic Retinopathy

Press Release by: Eyenuk, Inc.

Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.